KR950031064A - Zemfibrozil-containing pharmaceutical composition - Google Patents

Zemfibrozil-containing pharmaceutical composition Download PDF

Info

Publication number
KR950031064A
KR950031064A KR1019950012052A KR19950012052A KR950031064A KR 950031064 A KR950031064 A KR 950031064A KR 1019950012052 A KR1019950012052 A KR 1019950012052A KR 19950012052 A KR19950012052 A KR 19950012052A KR 950031064 A KR950031064 A KR 950031064A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
gemfibrozil
adjuvant
composition according
ethylhexyl
Prior art date
Application number
KR1019950012052A
Other languages
Korean (ko)
Inventor
페케테 팔
펠너 에르쩨베트
산도르팔비 안드레아
베쩨흐 데네스
유팔루씨 기외르기
고라 마그돌나
클레보비치 임레
드라반트 산도르
만디 아틸라
마로쉘리 비보르카
스잔토 마르타
스즐라비 수자
Original Assignee
사바 키스, 아틸라 만디
에지스 지오기스제르기아르 알티.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU9401506A external-priority patent/HU212428B/en
Application filed by 사바 키스, 아틸라 만디, 에지스 지오기스제르기아르 알티. filed Critical 사바 키스, 아틸라 만디
Publication of KR950031064A publication Critical patent/KR950031064A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 활성성분으로서 젬피브로질을 함유하고 계면활성제로서 조성물의 젬피브로질 함량에 관련하여 0.05 내지 0.5중량%의 양으로 비스-(2-에틸헥실)-소디움 술포속시네이트를 포함하는 종래의 약제학적 보조제를 함유하는 경구용 고형 약제학적 조성물에 관한 것이다.The present invention comprises bis- (2-ethylhexyl) -sodium sulfosuccinate in an amount of 0.05 to 0.5% by weight with respect to the gemfibrozil content of the composition as a surfactant and containing gemfibrozil as an active ingredient. Oral solid pharmaceutical composition containing a pharmaceutical adjuvant.

본 발명에 따르는 약제학적 조성물은 상대적으로 적은 양의 계면활성제를 함유하고, 상이한 배치중에서 균일한 활성성분의 용해를 제공하며 용해속도의 표준편차는 낮다.The pharmaceutical compositions according to the present invention contain relatively small amounts of surfactants, provide uniform dissolution of the active ingredient in different batches and have a low standard deviation of dissolution rate.

Description

젬피브로질 함유 약제학적 조성물Zemfibrozil-containing pharmaceutical composition

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

제1도는 본 발명 캡슐의 활성성분의 방출을 나타내는 그래프도, 제2도는 시판되는 캡슐의 활성성분의 방출을 나타내는 그래프도, 제3도는 캡슐로부터의 방출의 표준편차를 나타내는 그래프도.1 is a graph showing the release of the active ingredient of the capsule of the present invention, Figure 2 is a graph showing the release of the active ingredient of the commercially available capsule, Figure 3 is a graph showing the standard deviation of the release from the capsule.

Claims (10)

활성성분으로서 젬피브로질을 함유하고 계면활성제로서 조성물의 젬피브로질 함량에 관련하여 0.05 내지 0.5중량%의 양으로 비스-(2-에틸헥실)-소디움 술포속시네이트를 포함하는 종래의 약제학적 보조제를 함유하는 경구용 고형 약제학적 조성물.Conventional pharmaceutical formulations comprising gemfibrozil as active ingredient and bis- (2-ethylhexyl) -sodium sulfosuccinate in an amount of 0.05 to 0.5% by weight relative to the gemfibrozil content of the composition as a surfactant Oral solid pharmaceutical compositions containing adjuvants. 제1항에 있어서, 비스-(2-에틸헥실)-소디움 술포속시네이트의 양이 조성물의 젬피브로질의 0.1 내지 0.4%인 것을 특징으로 하는 약제학적 조성물.2. The pharmaceutical composition of claim 1, wherein the amount of bis- (2-ethylhexyl) -sodium sulfosuccinate is 0.1 to 0.4% of gemfibrozil of the composition. 제1항 또는 제2항에 있어서, 보조제가 충전제, 바람직하게는 미정질 셀룰로오스, 락토오스, 만니톨, 전분, 셀룰로오스 또는 인산 칼슘인 것을 특징으로 하는 약제학적 조성물.The pharmaceutical composition according to claim 1 or 2, wherein the adjuvant is a filler, preferably microcrystalline cellulose, lactose, mannitol, starch, cellulose or calcium phosphate. 제1항 또는 제2항에 있어서, 보조제가 결합제, 바람직하게는 젤라틴, 폴리비닐 피롤리돈, 히드록시프로필 메틸 셀룰로오즈, 폴리비닐 알코올 또는 폴리비닐 부티랄인 것을 특징으로 하는 약제학적 조성물.The pharmaceutical composition according to claim 1 or 2, wherein the adjuvant is a binder, preferably gelatin, polyvinyl pyrrolidone, hydroxypropyl methyl cellulose, polyvinyl alcohol or polyvinyl butyral. 제1항 또는 제2항에 있어서, 보조제가 붕괴제, 바람직하게는 전분, 카르복시메틸 전분, 카르복시메틸 셀룰로오스, 또는 교차 결합된 폴리비닐 피롤리돈인 것을 특징으로 하는 약제학적 조성물.The pharmaceutical composition according to claim 1 or 2, wherein the adjuvant is a disintegrant, preferably starch, carboxymethyl starch, carboxymethyl cellulose, or crosslinked polyvinyl pyrrolidone. 제1항 또는 제2항에 있어서, 보조제가 윤활제, 바람직하게는 스테아르산 마그네슘, 스테아르산 칼슘, 스테아르산, 수소처리된 캐스터유 또는 탈크인 것을 특징으로 하는 약제학적 조성물.The pharmaceutical composition according to claim 1 or 2, wherein the adjuvant is a lubricant, preferably magnesium stearate, calcium stearate, stearic acid, hydrotreated castor oil or talc. 제1항 또는 제2항에 있어서, 보조제가 슬라이딩제, 바람직하게는 콜로이드상 실리산 또는 탈크인 것을 특징으로 하는 약제학적 조성물.The pharmaceutical composition according to claim 1 or 2, wherein the adjuvant is a sliding agent, preferably colloidal silicic acid or talc. 제1항 내지 7항중 어느 한 항에 있어서, 캡슐, 정제 또는 필름-코팅된 정제의 형태인 것을 특징으로 하는 약제학적 조성물.The pharmaceutical composition according to any one of claims 1 to 7, which is in the form of a capsule, tablet or film-coated tablet. 활성성분으로서 젬피브로질을 함유하고 계면활성제로서 조성물의 젬피브로질 함량에 관련하여 0.05 내지 0.5중량%의 양으로 비스-(2-에틸헥실)-소디움 술포숙시네이트를 포함하는 종래의 약제학적 보조제를 함유하는 경구용 고형 약제학적 조성물의 제조방법.Conventional pharmaceuticals containing gemfibrozil as active ingredient and bis- (2-ethylhexyl) -sodium sulfosuccinate in an amount of 0.05 to 0.5% by weight relative to the gemfibrozil content of the composition as a surfactant A method for preparing an oral solid pharmaceutical composition containing an adjuvant. 제9항에 있어서, 조성물의 젬피브로질 함량과 관련하여 0.1 내지 0.4%의 양으로 비스-(2-에틸헥실)-소디움 술포숙시네이트를 사용하는 것을 포함하는 것을 특징으로 하는 방법.10. The method of claim 9, comprising using bis- (2-ethylhexyl) -sodium sulfosuccinate in an amount of 0.1 to 0.4% with respect to the gemfibrozil content of the composition. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임※ Note: The disclosure is based on the initial application.
KR1019950012052A 1994-05-13 1995-05-13 Zemfibrozil-containing pharmaceutical composition KR950031064A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9401506A HU212428B (en) 1994-05-13 1994-05-13 Process to prepare pharmaceutical compositions containing gemfibrozyl
HUP9401506 1994-05-13

Publications (1)

Publication Number Publication Date
KR950031064A true KR950031064A (en) 1995-12-18

Family

ID=10985186

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950012052A KR950031064A (en) 1994-05-13 1995-05-13 Zemfibrozil-containing pharmaceutical composition

Country Status (4)

Country Link
KR (1) KR950031064A (en)
BG (1) BG62234B1 (en)
RU (1) RU2152209C1 (en)
YU (1) YU29395A (en)

Also Published As

Publication number Publication date
RU2152209C1 (en) 2000-07-10
YU29395A (en) 1998-07-10
BG99630A (en) 1996-01-31
BG62234B1 (en) 1999-06-30

Similar Documents

Publication Publication Date Title
AU597471B2 (en) Stabilized ace inhibitor compositions
AU2002301782B2 (en) Clopidogrel bisulfate tablet formulation
KR100397082B1 (en) Pharmaceutical formulations containing ibuprofen and codeine
CA2521325A1 (en) Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
ES534096A0 (en) PROCEDURE FOR OBTAINING ADMINISTRABLE PHARMACEUTICAL TABLETS VIA ORAL
ATE307569T1 (en) GELABLE PHARMACEUTICAL COMPOSITIONS
US4929605A (en) Pharmaceutical composition for piperidinoalkanol derivatives
IE881195L (en) Ibuprofen sustained release matrix
PE20001036A1 (en) BIOADHESIVE TABLETS FOR PROGRESSIVE HYDRATION AND METHODS FOR THEIR PREPARATION AND USE
DK0869772T3 (en) Bioadhesive solid dosage form
HUT76325A (en) Solid pharmaceutical compositions containing (s)-2-(4-isobutylphenyl) propionic acid active ingredient and microcrystalline cellulose and colloidal silica as excipients
KR100456933B1 (en) Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route
JPS63165320A (en) Solid composition and manufacture
RU97100851A (en) SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING (S) -2- (4-ISOBUTYLPHENYL) PROPIONIC ACID AS AN ACTIVE INGREDIENT AND MICROCRYSTALLINE CELLULOSE OXYCEUM
US5322698A (en) Process for the preparation of a tablet or dragee composition containing a heat-, light- and moisture-sensitive active ingredient having monoclinic crystal structure
RU2002123182A (en) CONTAINING IBUPROFEN COMPOSITION
SI8710406B (en) Sustained release tablets on the basis of high molecular weight hydroxypropylmethylcellulose and a process for their manufacture
KR950031064A (en) Zemfibrozil-containing pharmaceutical composition
RU98123101A (en) The pharmaceutical compositions and pharmaceutical preparations containing potassium, sodium and Tris oxaprozin salt formulations, their application to eliminate or reduce pain in a mammal for the treatment of inflammation and disorders associated with inflammation in mammals, the production process of pharmaceutical preparations
IE60323B1 (en) Pharmaceutical composition for piperidinoalkanol derivatives
CA2074580C (en) Solid pharmaceutical composition for oral administration containing dapiprazole
US3729563A (en) Method of treating movement disorders
JPH11349479A (en) Stable enalapril maleate tablet
JP4824224B2 (en) Sugar-coating preparations
RU2002121503A (en) GALENOV DRUG WITH PROPOSED RELEASE OF MOLSIDOMIN, INTENDED FOR ORAL ADMINISTRATION

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
NORF Unpaid initial registration fee